Articles

How do you calculate 340B savings?

Multiply the 340B units by the gap between a reference price and the 340B price, once against WAC and once against the GPO price, then bridge gross savings to net savings.

340B savings on a product line are the units bought at the 340B price times the gap between a reference price and that 340B price. For 1,500 units bought at $405 instead of a WAC of $865, savings are $690,000; against a GPO price of $780 they are $562,500. Both figures are gross: net savings come after Medicaid, fees and restrictions.

Worked in full in The 340B Program Handbook by Julian R. Sterling, with every figure reproduced in a free workbook.Get the DRM-free PDF, $19.99 →

What 340B savings are

The 340B Drug Pricing Program does not pay a covered entity anything. As read in November 2026 in 42 U.S.C. 256b(a)(1), each manufacturer of covered outpatient drugs signs an agreement under which a covered entity pays no more than a ceiling price, and the manufacturer must offer the drug at or below that price whenever it sells the drug to any other purchaser. Under 42 CFR 10.10, the ceiling price is the average manufacturer price of the preceding quarter less the unit rebate amount, calculated to six decimal places and published by HRSA rounded to two. What a hospital or health center calls its 340B savings is therefore a cost it did not incur: the difference between what it paid at the 340B price and what it would have paid for the same unit without the program.

That definition settles two points before any arithmetic. Savings exist only on units really bought at the 340B price, and only on units the entity was entitled to buy that way: dispensed to a patient of the entity in the sense of HRSA's 1996 patient definition (61 FR 55156), at a site registered in HRSA's OPAIS database and, for an off-site hospital clinic, listed with outpatient costs and charges on the most recently filed Medicare cost report (88 FR 73859). A unit that fails either test is not a saving. It is a repayment that has not been found yet.

The three prices behind every unit

Every line of a 340B savings report rests on three prices for the same unit:

Which higher price is the fair comparison depends on who buys. The statute, at 42 U.S.C. 256b(a)(4)(L)(iii), makes it a condition for a disproportionate share hospital (and, through subparagraph (M), for children's and free-standing cancer hospitals) that it does not obtain covered outpatient drugs through a group purchasing organization. For such a hospital, an outpatient unit that cannot be bought at 340B is bought on a non-GPO account, which the book's model prices at WAC. HRSA lists its Policy Release 2013-1, which explained the prohibition, as vacated by a federal district court on March 31, 2026; how HRSA would apply the prohibition after that decision was not confirmed when this page was written, so ask the program's counsel before changing any purchasing practice. Federally qualified health centers are not subject to that prohibition, and for them a GPO price may be the real alternative.

Step 1: count the 340B units

Start from dispensations, not from invoices. In a mixed-use area or at a contract pharmacy, drugs are often dispensed from a neutral inventory and replenished later at the 340B price, once the split-billing software or the TPA has accumulated a whole package of eligible units. Purchases in a month therefore lag the care, and a remainder sits in the accumulator at year end. Counting the eligible units dispensed, remainder included, places the savings in the period in which the patients were treated.

Three groups of units stay out of the count. Inpatient units are not covered outpatient drugs and belong on the GPO account. Outpatient units that fail the patient definition, or that were dispensed at a site before its 340B start date, belong on the WAC account. Medicaid fee-for-service claims at a carve-out location are never 340B (the article on carve-in and carve-out explains why).

Step 2: choose the reference price, then keep both

Measured against WAC, savings answer the question: what would these units have cost us outside the program? For a hospital under the GPO prohibition, that is the cash it would really have spent on those outpatient units. Measured against the GPO price, savings answer a different question: how much better is 340B than the best negotiated contract we know? A board, a lender or a health center's governing body may prefer the second figure because it is more conservative. Neither is wrong. Each answers its own question, and printing only the larger one as the program's savings is how a report loses credibility the first time someone checks it.

Use the prices in force on the date of purchase. Ceiling prices change every quarter, and a WAC increase in the middle of the year raises the savings of the units bought after it, not before.

Step 3: multiply, line by line

Gross savings on a product line equal the reference price less the 340B price, times the 340B units. A sample line, not the book's case, shows the arithmetic: 1,500 units of an injectable bought at a 340B price of $405, where the GPO price is $780 and WAC is $865. Every price is a teaching assumption, not a market figure.

LineAmount
340B units dispensed and replenished1,500
340B price per unit$405
GPO price per unit$780
WAC per unit$865
Gross savings against WAC: ($865 - $405) x 1,500$690,000
Gross savings against the GPO price: ($780 - $405) x 1,500$562,500

The same 1,500 units are worth $690,000 or $562,500, depending on the question asked. Repeat the calculation for each product line, add the lines, and keep the two totals side by side in every report, each labeled with its reference price.

Step 4: from gross savings to net savings

Gross savings are not what the program leaves the entity. Four deductions stand between the two figures, and each must appear exactly once:

  1. Restriction loss. Start from potential gross savings on every eligible unit. Units that a manufacturer no longer sells at the 340B price through a given contract pharmacy are lost before anything is captured.
  2. Medicaid discount passed to the state. At a carve-in site where the state pays for the drug at acquisition cost, the discount on Medicaid fee-for-service units goes to the state.
  3. Contract pharmacy dispensing fees, paid to each pharmacy per claim.
  4. TPA fees, per claim or as a percentage of the reimbursement (see how contract pharmacy fees work).

Potential gross savings less the restriction loss give the gross savings captured; less the Medicaid discount, the dispensing fees and the TPA fees, they give net savings. Build the bridge by channel (hospital-administered drugs, the in-house retail pharmacy, the contract pharmacies) because the deductions do not fall evenly: a drug administered in an infusion department pays no dispensing fee, while a contract pharmacy line carries every one of them.

Savings are not net benefit

Finance teams often keep a second figure for contract pharmacies: payer reimbursement less 340B cost less fees, claim by claim. That is net benefit, a cash measure, and it counts what payers pay. Savings count what the entity avoided paying. The two differ whenever a payer reimburses more or less than WAC, so they should never be added together or swapped inside one report.

When savings arrive as rebates

As read in November 2026, HRSA's revised rebate pilot (91 FR 48883, August 3, 2026) was scheduled to start on January 1, 2027 for some drugs selected for Medicare price negotiation. For those drugs the entity would buy at WAC through its existing 340B wholesaler account and later receive a rebate equal to WAC less the ceiling price per unit dispensed, paid or denied within 10 calendar days of a complete claims submission, with plans that must give covered entities at least 45 calendar days from the date of dispense to submit claims data. Hospital groups were reported to have sued in October 2026 to block the pilot; as reported on October 12, 2026 it remained scheduled, and no later ruling was confirmed here. If it applies, the gross saving on those lines would in principle stay the same, but it would arrive later, part of it could be denied, and the cash advanced in the meantime would carry a cost of capital that deserves its own line in the report.

The same steps in the book

The case is fictional: Talbryn Regional Medical Center, a 240-bed private non-profit hospital in the 340B Program as a disproportionate share hospital, with three eligible sites, an in-house retail pharmacy and four contract pharmacies served through one TPA, measured for calendar 2025. Every price, volume, fee and rate of the case is a teaching assumption, not a market figure, and the facts of your own program govern.

The units Talbryn actually bought at 340B in 2025 save $9,501,366.70 against WAC and $7,782,234.50 against the GPO price, a difference of $1,719,132.20: the board reads two numbers that answer two questions. Potential gross savings are $10,310,966.70. A single-pharmacy restriction on one biologic removes $809,600.00, the carve-in passes $956,399.00 to the state, and contract pharmacy dispensing and TPA fees take $99,594.00 and $46,271.60. Net savings are $8,399,102.10, 81.46 percent of the potential, and the drugs administered in the infusion and oncology departments alone bring $4,639,600.00 of them.

Mistakes that recur in savings reports

Rules are described as read in November 2026 from 42 U.S.C. 256b, 42 CFR 10.10, HRSA's notices 61 FR 55156 (October 24, 1996), 88 FR 73859 (October 27, 2023) and 91 FR 48883 (August 3, 2026), and HRSA's Office of Pharmacy Affairs pages, and they change. No state rule is described. This page is education, not legal advice: ask the program's counsel how any rule applies to your program.

Questions people ask

What is the formula for 340B savings?

Gross savings equal the reference price less the 340B price, times the 340B units dispensed. The reference price is WAC, or the GPO price for a second, more conservative reading. Net savings then deduct restriction losses, the Medicaid discount passed to the state, and contract pharmacy and TPA fees.

Should 340B savings be measured against WAC or the GPO price?

Both, side by side. WAC answers what the units would have cost outside the program for a hospital that may not use a GPO for outpatient drugs; the GPO price answers how much better 340B is than a negotiated contract. Label each figure with its reference price.

Are 340B savings the same as 340B revenue?

No. Savings are a cost avoided on drugs bought at the 340B price. Revenue, or net benefit at a contract pharmacy, counts what payers reimburse less costs and fees. Keep them on separate lines.

Do Medicaid units count in 340B savings?

At a carve-in site the units are bought at 340B, but where the state pays at acquisition cost the discount passes to the state and is deducted in the bridge. At a carve-out site, Medicaid fee-for-service units are not bought at 340B and never enter the savings.

How is the ceiling price set?

As read in November 2026 in 42 CFR 10.10, it is the average manufacturer price of the preceding quarter less the unit rebate amount, calculated to six decimals and published by HRSA rounded to two. Ask the program's counsel how a given price applies.

Read the whole case

This article is one step of The 340B Program Handbook. The book follows one hospital through a full 340B year: three eligible sites and one that had to wait, the patient definition applied claim by claim, three purchase accounts and an accumulator, a carve-in and a carve-out, four contract pharmacies and their TPA, the bridge from potential to net savings, a manufacturer restriction, a rebate scenario and a self-audit that ends in a self-disclosure.

Paperback PDF edition, $19.99 Book page and free files

Free: the 340B savings calculator in Excel.

Also on this site

Case figures computed by the book's model; the hospitals and pharmacies are fictional and every price, fee and rate is a teaching assumption. Figures checked on 20 November 2026. Rules described as read on the dates given; not legal advice.